Vaccines

Enesi Pharma's ImplaVax® Solid-Dose and Needle-Free Vaccination Platform Wins Best New Vaccine Technology/Platform Award at the World Vaccine Congress

Retrieved on: 
Thursday, October 1, 2020
Medical specialties, Medicine, Vaccination, Virology, Health, Vaccines, Medical research, Vaccine, Herpes simplex research

The Vaccine Industry Excellence (ViE) Awards honour and recognise the efforts, accomplishments, and positive contributions of companies and individuals in the vaccine industry and are a highlight of the World Vaccine Congress.

Key Points: 
  • The Vaccine Industry Excellence (ViE) Awards honour and recognise the efforts, accomplishments, and positive contributions of companies and individuals in the vaccine industry and are a highlight of the World Vaccine Congress.
  • "We are delighted to win the Best New Vaccine Technology/Platform category at such a prestigious global vaccine event.
  • Enesi Pharma is developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax technologies.
  • Our ImplaVax-enabled vaccination products leverage our innovative unit solid-dose formulation and needle-free delivery technologies and are applicable across all vaccine formats.

COVID-19 Vaccine & Therapeutics Clinical Trial Analysis 2020 Featuring Major Players - Pfizer, GSK, Inovio Pharma, J&J, Novavax, Heat Biologics, Sanofi, BioNTech, Vaxart, and Vir Biotechnology - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 30, 2020
Health, General Health, Health, Articles, Medical research, Vaccines, COVID-19 vaccine, Inovio Pharmaceuticals, Pfizer, Sanofi, Novavax, BioNTech, GlaxoSmithKline, Operation Warp Speed

COVID-19 Vaccine & Therapeutics Clinical Trial Analysis 2020 provides the strategists, marketers and senior management with the critical information they need to assess the global COVID-19 vaccine & therapeutics clinical trial analysis 2020 market.

Key Points: 
  • COVID-19 Vaccine & Therapeutics Clinical Trial Analysis 2020 provides the strategists, marketers and senior management with the critical information they need to assess the global COVID-19 vaccine & therapeutics clinical trial analysis 2020 market.
  • Major players in the COVID-19 vaccine and therapeutics clinical trial analysis market are Pfizer, GlaxoSmithKline (GSK), Inovio Pharmaceuticals, Johnson & Johnson (J&J), Novavax Inc., Heat Biologics, Sanofi, BioNTech, Vaxart, and Vir Biotechnology.
  • Many research institutes, healthcare organizations and biopharmaceutical companies worldwide are conducting clinical trials for COVID-19 vaccines and therapeutics.
  • The COVID-19 vaccine and therapeutics clinical trial analysis report consists of drugs and vaccines which are under clinical trials for the treatment of COVID-19.

COVID-19 Vaccines Pipeline Report, Q3 2020 Edition - Big Pharma and Biotech Race to make Vaccines Available by the End of 2020 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 30, 2020
Health, General Health, Health, Medicine, Vaccines, Medical research, COVID-19 vaccine, Vaccine, BCG vaccine, AstraZeneca, Bharat Biotech, CoronaVac

The "COVID-19 Vaccines - Big Pharma and Biotech Race to make Vaccines Available by the End of 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "COVID-19 Vaccines - Big Pharma and Biotech Race to make Vaccines Available by the End of 2020" report has been added to ResearchAndMarkets.com's offering.
  • AstraZeneca has formed an alliance with the University of Oxford to assist in the development, manufacturing, marketing and distribution of a potential COVID-19 Vaccination.
  • The BCG vaccine, traditionally used to prevent tuberculosis, is the only other vaccine undergoing phase III clinical trials for COVID-19 in July 2020.
  • Vaccines at a less advanced stages of development offer an alternative to the vaccines currently undergoing Phase III testing.

Altimmune to Present at Upcoming Investor Conferences

Retrieved on: 
Wednesday, September 30, 2020
Life sciences, Biotechnology, Articles, Pharmaceutical industry, Vaccines, Vaccination, Vaccine, Virology, Biopharmaceutical, Live attenuated influenza vaccine

GAITHERSBURG, Md., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following upcoming virtual investor conferences in October:

Key Points: 
  • GAITHERSBURG, Md., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following upcoming virtual investor conferences in October:
    The H.C. Wainwright presentation will be webcast and can be accessed by visiting the investor relations section of the company's website at www.altimmune.com under Events/Presentations.
  • Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease.
  • The Companys diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID), anthrax (NasoShield) and influenza (NasoVAX); an intranasal immune modulating therapeutic for COVID-19 (T-COVID); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell).
  • For more information on Altimmune, please visit www.altimmune.com .

Coronavirus Disease (COVID-19) Pipeline Review, H2 2020 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 30, 2020
Health, Infectious diseases, Zoonoses, Health, Respiratory diseases, Medicine, Animal virology, Coronavirus, Vaccines

Coronavirus Disease - Pipeline Review, H2 2020, provides an overview of the Coronavirus Disease (Infectious Disease) pipeline landscape.

Key Points: 
  • Coronavirus Disease - Pipeline Review, H2 2020, provides an overview of the Coronavirus Disease (Infectious Disease) pipeline landscape.
  • Coronavirus Disease - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Coronavirus Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Coronavirus Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Coronavirus Disease 2019 (COVID-19) and features dormant and discontinued projects.
  • Formulate corrective measures for pipeline projects by understanding Coronavirus Disease (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Stabilitech Biopharma announces name change to iosBio

Retrieved on: 
Wednesday, September 30, 2020
Medical specialties, Health, Medicine, Medical research, Vaccination, Virology, Vaccines, Vaccine, Vaxart, COVID-19 vaccine

Burgess Hill, UK, 30 September 2020, STABILITECH BIOPHARMA (the Company), a UK-based biotechnology company developing next generation vaccines that can be administered orally, announces today that the Company has been renamed iosBio.

Key Points: 
  • Burgess Hill, UK, 30 September 2020, STABILITECH BIOPHARMA (the Company), a UK-based biotechnology company developing next generation vaccines that can be administered orally, announces today that the Company has been renamed iosBio.
  • Chairman of iosBio, Wayne Channon said, Establishing a new corporate identity is part of our goal to become a disruptor in the vaccine development and delivery space.
  • iosBio is using its patented OraPro oral delivery vaccine platform to develop a pipeline of orally administered vaccine candidates for infectious diseases including COVID-19, Zika and influenza.
  • iosBio is developing OraPro-COVID-19, a self-administered oral vaccine candidate against coronavirus.

Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Older Adult Age Cohorts in Phase 1 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)

Retrieved on: 
Tuesday, September 29, 2020
Other Health, Research, Pharmaceutical, Oncology, Infectious diseases, Genetics, Clinical trials, Science, Cardiology, Biotechnology, Other Science, Health, Articles, Vaccines, Life sciences, Branches of biology, Zika virus, Medical research, Moderna, Zika virus vaccine, National Institutes of Health, Messenger RNA, Zika fever, mRNA-1273, Moderna’s Prophylactic Vaccines Modality, Moderna

This analysis found that both the 25 g and 100 g dose levels were generally well-tolerated in both age cohorts.

Key Points: 
  • This analysis found that both the 25 g and 100 g dose levels were generally well-tolerated in both age cohorts.
  • Results from a non-human primate preclinical viral challenge study evaluating mRNA-1273 were recently published in The New England Journal of Medicine.
  • On July 14, an interim analysis of the original cohorts in the NIH-led Phase 1 study of mRNA-1273 was published in The New England Journal of Medicine.
  • Modernas investigational Zika vaccine (mRNA-1893), currently in a Phase 1 study, was granted FDA Fast Track designation in August 2019.

ILiAD Biotechnologies Reports Positive Topline Results from Phase 2b Trial for Pertussis Vaccine Candidate BPZE1

Retrieved on: 
Tuesday, September 29, 2020
Whooping cough, Medical specialties, Burkholderiales, Clinical medicine, RTT, Medicine, Vaccination, Vaccines, Bordetella pertussis, Pertussis vaccine, Bordetella, Vaccine

WESTON, Fla., Sept. 29, 2020 (GLOBE NEWSWIRE) -- ILiAD Biotechnologies, LLC (ILiAD) today presented positive topline Phase 2b trial results of its lead pertussis vaccine candidate BPZE1 at the virtual World Vaccine Congress.

Key Points: 
  • WESTON, Fla., Sept. 29, 2020 (GLOBE NEWSWIRE) -- ILiAD Biotechnologies, LLC (ILiAD) today presented positive topline Phase 2b trial results of its lead pertussis vaccine candidate BPZE1 at the virtual World Vaccine Congress.
  • BPZE1, a live attenuated pertussis vaccine, met both primary endpoints of overall safety and induction of mucosal immunity.
  • BPZE1 was differentiated in its ability to demonstrate induction of broad mucosal immunity against whole cell extract (WCE) and pertussis-specific protein antibodies.
  • Its lead candidate, BPZE1, is the most advanced next generation vaccine for the prevention of pertussis (whooping cough), a serious disease caused by Bordetella pertussis.

North America Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country

Retrieved on: 
Tuesday, September 29, 2020
Vaccination, Medical specialties, RTT, Health, Vaccines, Influenza, Live attenuated influenza vaccine

DUBLIN, Sept. 29, 2020 /PRNewswire/ -- The "North America Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 29, 2020 /PRNewswire/ -- The "North America Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.
  • North America influenza treatment market is expected to grow by 2.3% annually in the forecast period and reach $569.8 million by 2030 driven by rising incidences of influenza, growing awareness and need for new drugs and treatment in the region.
  • The balanced (most likely) projection is used to quantify North America influenza treatment market in every aspect of the classification from perspectives of Product Type, Influenza Type, Administration Route, Distribution Channel, and Country.
  • Specifically, potential risks associated with investing in North America influenza treatment market are assayed quantitatively and qualitatively through a Risk Assessment System.

Superior HealthPlan's Fluvention Program Encourages Vaccines, Education During COVID-19 Pandemic

Retrieved on: 
Tuesday, September 29, 2020
Articles, Medical specialties, Health, RTT, Vaccines, Influenza vaccine, Flu season, Influenza, Pandemic, Medi-Cal, Centene Corporation, Vaccine

Superior HealthPlan is launching its annual Fluvention program to encourage Texas residents to get a flu vaccine.

Key Points: 
  • Superior HealthPlan is launching its annual Fluvention program to encourage Texas residents to get a flu vaccine.
  • As the pandemic continues, Superior also wants to help people better understand the differences between the flu and COVID-19.
  • "To help protect against the flu, we encourage members to schedule their vaccination appointments as soon as possible," said Dr. David Harmon, Chief Medical Director at Superior.
  • Superior is a wholly-owned subsidiary of Centene Corporation, a leading multi-national healthcare enterprise offering both core Medicaid and specialty services.